These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16272651)

  • 1. [Serum calcium levels at first renal replacement therapy and patients survival].
    Osawa Y; Aoike I; Sakurabayashi T; Miyazaki S; Yuasa Y; Suzuki M
    Clin Calcium; 2005 Sep; 15 Suppl 1():167-72; discussion 172. PubMed ID: 16272651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.
    Wazny LD; Raymond CB; Lesperance EM; Bernstein KN
    CANNT J; 2008; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL; Hristova M; Ho LT; Sprague SM
    Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.
    Noordzij M; Korevaar JC; Dekker FW; Boeschoten EW; Bos WJ; Krediet RT; Bossuyt PM; Geskus RB;
    Blood Purif; 2008; 26(3):231-7. PubMed ID: 18305386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
    Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
    Izumi M; Shirai K; Ito K; Miyamoto T; Matsumoto A; Takenaka Y; Nakagawa K; Yamanashi T; Takamitsu Y; Nakanish T
    Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients.
    Phelan PJ; O'Kelly P; Walshe JJ; Conlon PJ
    Ren Fail; 2008; 30(4):423-9. PubMed ID: 18569917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low prevalence of hyperphosphatemia independent of residual renal function in peritoneal dialysis patients.
    Dong J; Wang H; Wang M
    J Ren Nutr; 2007 Nov; 17(6):389-96. PubMed ID: 17971311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
    Shastri J; Tran A; Covit A; Pepe J; Sherman RA
    J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
    Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
    Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of calcium infusion on calcitonin and parathyroid hormone concentrations in normal and hemodialyzed subjects.
    Isaac R; Nivez MP; Piamba G; Fillastre JP; Ardaillou R
    Clin Nephrol; 1975 Jan; 3(1):14-7. PubMed ID: 1126058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
    Blair D; Byham-Gray L; Lewis E; McCaffrey S
    J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.
    Slinin Y; Foley RN; Collins AJ
    J Am Soc Nephrol; 2005 Jun; 16(6):1788-93. PubMed ID: 15814832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
    Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
    Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.